PCR Machines in New York

Empire Genomics is a molecular diagnostics company specializing in Fluorescence in Situ Hybridization (FISH) and Chromogenic in Situ Hybridization (CISH) probes for clinical diagnostics and research applications. Founded in 2006 by Dr. Norma J. Nowak and based in Depew, New York, the company originated from research at Roswell Park Comprehensive Cancer Institute. Empire Genomics offers a comprehensive portfolio of over 2,000 FISH probes optimized for cancer research, genetic testing across 200+ health conditions, and routine clinical diagnostics. Their product line includes manual and automated FISH probes, break-apart and fusion probes, single and dual-color probes, custom probe design services, and ancillary reagents. The company provides full-service FISH processing with rapid turnaround (next-day shipping for in-stock items; custom designs in two weeks). Empire Genomics supplies 44 of the top 50 US cancer centers and has sold over 1 million tests globally. Quality assurance includes BAC End Sequencing validation and access to a 645K+ clone library. Automation solutions include NeoPATH Pro for tissue, BioDot Cellwriter S for hematology, and ONCORE Pro for urine specimens.

Oxford Gene Technology (OGT) is a precision genomics company specializing in molecular diagnostics for clinical and research laboratories. The company develops and manufactures hybridization-based FISH (fluorescence in situ hybridization), NGS (next-generation sequencing), and array-based genomic solutions for haematological malignancies, solid tumours, cytogenetics, and rare disease detection. OGT's primary product portfolio includes CytoCell FISH probes, SureSeq NGS panels, and CytoSure arrays. Recent offerings include the SureSeq Myeloid MRD Plus NGS Panel for minimal residual disease detection in acute myeloid leukaemia, and the FDA-authorized CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic for KMT2A-rearranged acute leukaemia. OGT provides end-to-end support from assay design through clinical implementation, including precision medicine partnering for clinical trial and companion diagnostic development. The company serves clinical diagnostic laboratories, research institutions, and oncology centers globally, with established partnerships and customer bases across North America, Europe, and international markets. OGT's technical support is provided by personnel with laboratory backgrounds, supporting implementation of test workflows and biomarker interrogation. The company holds FDA authorizations for companion diagnostics and operates under clinical laboratory standards for genomic testing.

ZeptoMetrix is a leading biotechnology company specializing in quality controls, assay development services, analytical reference materials, and proficiency testing for infectious disease diagnostics and analytical markets. Founded in 1999 and headquartered in Buffalo, New York, the company operates as a division of Antylia Scientific. ZeptoMetrix serves diagnostic microbiology, oncology, environmental testing, food & agriculture, cannabis & hemp, and pharmaceutical sectors. The company offers molecular controls for diagnostic testing, analytical reference materials including certified reference materials (CRMs) for environmental contaminants (PFAS, microplastics, pesticides, organotins), food safety standards, cannabis potency testing compounds, and pharmaceutical reference standards. ZeptoMetrix provides ISO 17043-accredited proficiency testing programs, viral lysates and culture fluids, seroconversion panels, monoclonal and polyclonal antibodies, ELISA kits, microbiological controls, and oncology molecular controls. With approximately 106-200 employees and ~$10M annual revenue, ZeptoMetrix serves global customers through direct sales and distributor networks, supported by comprehensive technical documentation and regulatory compliance resources.